Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency

Stock Information for Soligenix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Soligenix Inc.

Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines
New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
Tonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial Operations
Tonix Pharmaceuticals Presented Data on the Potential Mpox Vaccine TNX-801 in "Using Synthetic Biology to Battle Mpox" Talk at Immunology Symposium at the University of Alberta
Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek
As Research Into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront - Tonix Targets It With FDA-Fast Track-Designated TNX-102 SL
Tonix Pharmaceuticals Presented Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium (MHSRS)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.